Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio

Contributed by: Business Wire

Logo

Tags

FDA

Health

Infectious Diseases

Research

Science

Biotechnology

TriLink BioTechnologies

More Like This

Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research

TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe

TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)

TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production

TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Samabriva is Set to Become a World Leader in Precision Biomanufacturing of Complex Molecules With the Announcement of a €4 Million Fundraising Round